D
BridgeBio Pharma, Inc.
BBIO
$32.19
-$0.82-2.48%
D
Sell
3/14/2023Downgrade
BridgeBio Pharma, Inc. (BBIO) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index.
BridgeBio Pharma, Inc. (BBIO) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index.
D
Sell
2/9/2023Upgraded
BridgeBio Pharma, Inc. (BBIO) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
BridgeBio Pharma, Inc. (BBIO) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
E
Sell
2/8/2023Downgrade
BridgeBio Pharma, Inc. (BBIO) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
BridgeBio Pharma, Inc. (BBIO) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
D
Sell
2/2/2023Upgraded
BridgeBio Pharma, Inc. (BBIO) was upgraded to D from D- on 2/2/2023 due to an increase in the volatility index.
BridgeBio Pharma, Inc. (BBIO) was upgraded to D from D- on 2/2/2023 due to an increase in the volatility index.
D
Sell
1/17/2023Downgrade
BridgeBio Pharma, Inc. (BBIO) was downgraded to D- from D on 1/17/2023 due to a decline in the volatility index and total return index.
BridgeBio Pharma, Inc. (BBIO) was downgraded to D- from D on 1/17/2023 due to a decline in the volatility index and total return index.
D
Sell
11/25/2022Upgraded
BridgeBio Pharma, Inc. (BBIO) was upgraded to D from D- on 11/25/2022 due to an increase in the volatility index and total return index.
BridgeBio Pharma, Inc. (BBIO) was upgraded to D from D- on 11/25/2022 due to an increase in the volatility index and total return index.
D
Sell
11/9/2022Downgrade
BridgeBio Pharma, Inc. (BBIO) was downgraded to D- from D on 11/9/2022 due to a major decline in the growth index and volatility index. Earnings per share declined from -$0.0672 to -$0.9284, operating cash flow declined 343.84% from -$30.45M to -$135.16M, and total revenue declined 99.54% from $73.75M to $338.
BridgeBio Pharma, Inc. (BBIO) was downgraded to D- from D on 11/9/2022 due to a major decline in the growth index and volatility index. Earnings per share declined from -$0.0672 to -$0.9284, operating cash flow declined 343.84% from -$30.45M to -$135.16M, and total revenue declined 99.54% from $73.75M to $338.
D
Sell
8/8/2022Upgraded
BridgeBio Pharma, Inc. (BBIO) was upgraded to D from D- on 8/8/2022 due to a substantial increase in the growth index, volatility index and total return index. Total revenue increased 4,253.36% from $1.69M to $73.75M, earnings per share increased from -$1.3463 to -$0.0672, and operating cash flow increased 81.04% from -$160.64M to -$30.45M.
BridgeBio Pharma, Inc. (BBIO) was upgraded to D from D- on 8/8/2022 due to a substantial increase in the growth index, volatility index and total return index. Total revenue increased 4,253.36% from $1.69M to $73.75M, earnings per share increased from -$1.3463 to -$0.0672, and operating cash flow increased 81.04% from -$160.64M to -$30.45M.
D
Sell
5/31/2022Upgraded
BridgeBio Pharma, Inc. (BBIO) was upgraded to D- from E+ on 05/31/2022.
BridgeBio Pharma, Inc. (BBIO) was upgraded to D- from E+ on 05/31/2022.
E
Sell
5/13/2022Downgrade
BridgeBio Pharma, Inc. (BBIO) was downgraded to E+ from D- on 5/13/2022 due to a noticeable decline in the growth index and total return index. Total revenue declined 86.85% from $12.89M to $1.69M, earnings per share declined from -$1.013 to -$1.3463, and operating cash flow declined 19.97% from -$133.9M to -$160.64M.
BridgeBio Pharma, Inc. (BBIO) was downgraded to E+ from D- on 5/13/2022 due to a noticeable decline in the growth index and total return index. Total revenue declined 86.85% from $12.89M to $1.69M, earnings per share declined from -$1.013 to -$1.3463, and operating cash flow declined 19.97% from -$133.9M to -$160.64M.
D
Sell
5/5/2022Upgraded
BridgeBio Pharma, Inc. (BBIO) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
BridgeBio Pharma, Inc. (BBIO) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
BridgeBio Pharma, Inc. (BBIO) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index.
BridgeBio Pharma, Inc. (BBIO) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index.
D
Sell
3/25/2022Downgrade
BridgeBio Pharma, Inc. (BBIO) was downgraded to D- from D on 3/25/2022 due to a decline in the total return index, volatility index and valuation index.
BridgeBio Pharma, Inc. (BBIO) was downgraded to D- from D on 3/25/2022 due to a decline in the total return index, volatility index and valuation index.
D
Sell
3/2/2022Upgraded
BridgeBio Pharma, Inc. (BBIO) was upgraded to D from D- on 3/2/2022 due to a large increase in the growth index. Total revenue increased 449.74% from $2.34M to $12.89M, and earnings per share increased from -$1.0632 to -$1.013.
BridgeBio Pharma, Inc. (BBIO) was upgraded to D from D- on 3/2/2022 due to a large increase in the growth index. Total revenue increased 449.74% from $2.34M to $12.89M, and earnings per share increased from -$1.0632 to -$1.013.
D
Sell
2/7/2022Downgrade
BridgeBio Pharma, Inc. (BBIO) was downgraded to D- from D on 2/7/2022 due to a major decline in the total return index and volatility index.
BridgeBio Pharma, Inc. (BBIO) was downgraded to D- from D on 2/7/2022 due to a major decline in the total return index and volatility index.
D
Sell
11/23/2021Upgraded
BridgeBio Pharma, Inc. (BBIO) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
BridgeBio Pharma, Inc. (BBIO) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
D
Sell
11/8/2021Downgrade
BridgeBio Pharma, Inc. (BBIO) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the growth index and valuation index. Total revenue declined 95.66% from $54.02M to $2.34M, earnings per share declined from -$0.6565 to -$1.0632, and EBIT declined 59.02% from -$94.02M to -$149.5M.
BridgeBio Pharma, Inc. (BBIO) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the growth index and valuation index. Total revenue declined 95.66% from $54.02M to $2.34M, earnings per share declined from -$0.6565 to -$1.0632, and EBIT declined 59.02% from -$94.02M to -$149.5M.
D
Sell
11/3/2021Downgrade
BridgeBio Pharma, Inc. (BBIO) was downgraded to D from D+ on 11/3/2021 due to a decline in the volatility index and total return index.
BridgeBio Pharma, Inc. (BBIO) was downgraded to D from D+ on 11/3/2021 due to a decline in the volatility index and total return index.
D
Sell
8/6/2021Upgraded
BridgeBio Pharma, Inc. (BBIO) was upgraded to D+ from D on 8/6/2021 due to a major increase in the total return index, growth index and valuation index. Total revenue increased 11,593.51% from $462 to $54.02M, earnings per share increased from -$1.1764 to -$0.6565, and EBIT increased 43.87% from -$167.5M to -$94.02M.
BridgeBio Pharma, Inc. (BBIO) was upgraded to D+ from D on 8/6/2021 due to a major increase in the total return index, growth index and valuation index. Total revenue increased 11,593.51% from $462 to $54.02M, earnings per share increased from -$1.1764 to -$0.6565, and EBIT increased 43.87% from -$167.5M to -$94.02M.
D
Sell
12/31/2019Upgraded
BridgeBio Pharma, Inc. (BBIO) was upgraded to D from D- on 12/31/2019 due to a significant increase in the solvency index, volatility index and total return index. The quick ratio increased from 7.59 to 13.45.
BridgeBio Pharma, Inc. (BBIO) was upgraded to D from D- on 12/31/2019 due to a significant increase in the solvency index, volatility index and total return index. The quick ratio increased from 7.59 to 13.45.
D
Sell
10/29/2019Downgrade
BridgeBio Pharma, Inc. (BBIO) was downgraded to D- from D on 10/29/2019 due to a noticeable decline in the growth index, total return index and volatility index.
BridgeBio Pharma, Inc. (BBIO) was downgraded to D- from D on 10/29/2019 due to a noticeable decline in the growth index, total return index and volatility index.
D
Sell
10/10/2019Upgraded
BridgeBio Pharma, Inc. (BBIO) was upgraded to D from D- on 10/10/2019 due to an increase in the growth index and total return index.
BridgeBio Pharma, Inc. (BBIO) was upgraded to D from D- on 10/10/2019 due to an increase in the growth index and total return index.
D
Sell
9/25/2019Downgrade
BridgeBio Pharma, Inc. (BBIO) was downgraded to D- from D on 9/25/2019 due to a noticeable decline in the volatility index.
BridgeBio Pharma, Inc. (BBIO) was downgraded to D- from D on 9/25/2019 due to a noticeable decline in the volatility index.
D
Sell
9/20/2019None
BridgeBio Pharma, Inc. (BBIO) was downgraded to D from U on 09/20/2019.
BridgeBio Pharma, Inc. (BBIO) was downgraded to D from U on 09/20/2019.
NASDAQ
03/18/2025 4:00PM Eastern
Quotes delayed
